false 0001496671 0001496671 2020-11-05 2020-11-05





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2020



Calithera Biosciences, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-36644   27-2366329

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


343 Oyster Point Blvd. Suite 200

South San Francisco, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 870-1000



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, 0.0001 par value   CALA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.02.

Results of Operations and Financial Condition.

On November 5, 2020, Calithera Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of this press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.





99.1    Press Release, dated November 5, 2020
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Calithera Biosciences, Inc.
Dated: November 5, 2020    

/s/ Susan M. Molineaux

      Susan M. Molineaux
      President and Chief Executive Officer
EX-99.1 2 d53133dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights

—Calithera to Provide Corporate Update via Conference Call and Webcast at

2:00 p.m. PT on November 5, 2020—

SOUTH SAN FRANCISCO, Calif., November 5, 2020 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the third quarter ended September 30, 2020.

“To date, 2020 has been a significant year for Calithera as we’ve made remarkable progress to advance our clinical development efforts across our pipeline and work toward reporting our first pivotal trial results with our lead candidate glutaminase inhibitor telaglenastat, while continuing to strengthen our cash position,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We look forward to reporting top-line results from our pivotal CANTATA trial evaluating telaglenastat in renal cell carcinoma in late fourth quarter of 2020 or early first quarter 2021. We also announced recently the initiation of the first clinical trial to evaluate our novel arginase inhibitor in cystic fibrosis, and the initiation of our first clinical trial evaluating telaglenastat in people with non-small cell lung cancer whose tumors have KEAP1 or NRF2 genetic mutations.”

Third Quarter 2020 and Other Recent Program Highlights



Progress continues toward top-line data readout of pivotal Phase 3 CANTATA randomized trial of telaglenastat and cabozantinib in advanced renal cell carcinoma (RCC). The CANTATA trial is a global, randomized, double-blind clinical trial of telaglenastat combined with cabozantinib, in patients with advanced or metastatic RCC who have received one or two prior treatments. The trial enrolled 444 patients at multiple centers globally. The primary endpoint is progression-free survival (PFS). Calithera expects to report top-line efficacy and safety data from the trial in late fourth quarter of 2020 or early first quarter 2021.



KEAPSAKE randomized trial evaluating telaglenastat in non-small cell lung cancer (NSCLC) patients with a KEAP1 or NRF2 genetic mutation enrolled first patient in September. Mutations in the KEAP1/NRF2 pathway, which occur in an estimated 20 percent of NSCLC patients, are associated with aggressive tumor growth and poor outcomes for patients. The double-blind KEAPSAKE trial will enroll approximately 120 patients with stage IV non-squamous NSCLC with tumors that have the KEAP1 or NRF2 mutation. Patients will be randomized to receive telaglenastat or placebo, in combination with pembrolizumab, carboplatin and pemetrexed. The study will evaluate the safety and investigator-assessed PFS of telaglenastat plus this standard-of-care chemo-immunotherapy regimen. Calithera anticipates sharing interim data from the KEAPSAKE trial in 2021.



ENTRATA Phase 2 study of telaglenastat with everolimus in RCC survival analysis completed. The ENTRATA trial was a randomized, double-blind, trial designed to evaluate the safety and efficacy of telaglenastat in combination with everolimus versus placebo with everolimus in patients with advanced clear cell RCC who have been treated with at least two prior lines of systemic therapy, including at least one prior VEGFR-targeted tyrosine kinase inhibitor. The trial enrolled 69 patients. The primary endpoint was PFS per investigator assessment with a predetermined threshold of p£0.2 one-sided. Top-line results were reported in June 2019. Telaglenastat, when added to everolimus, doubled the median PFS in heavily pretreated patients with advanced RCC to 3.8 months as compared to 1.9 months for everolimus alone, and reduced the risk of disease progression or death by 36% (HR=0.64, p=0.079 one-sided). Although the study was not powered for survival, it was evaluated as a secondary endpoint, and is now mature enough to be reported. Based on the data cutoff of September 30, 2020, the median overall survival is 14.4 months vs. 9.7 months in the telaglenastat and control arms, respectively (HR=0.80, p=0.24 one-sided).



Pfizer clinical collaboration investigating the CDK4/6 inhibitor IBRANCE® with telaglenastat expanded to evaluate the combination in pancreatic cancer patients. In July 2019, Calithera initiated a Phase 1/2 trial of the combination of telaglenastat plus Ibrance in patients with solid tumors including


expansion cohorts in KRAS-mutated colorectal cancer and KRAS-mutated non-small cell lung cancer. In November, Calithera announced the expansion of this collaboration to include an additional cohort of patients with pancreatic ductal adenocarcinoma (PDAC) whose tumors harbor mutations in both KRAS and CDKN2A.



CB-280 arginase inhibitor program advanced. In October, Calithera presented a trial in progress poster at the North American Cystic Fibrosis 2020 Virtual Conference. The presentation included preclinical study results which suggest CB-280 significantly improved lung function and reduced Pseudomonas aeruginosa colony-forming units in pre-clinical models. Arginase inhibition with CB-280 resulted in improved central airway resistance in CFTR knockout mice, and decreased lung infection in wild type and DeltaF508-CFTR-expressing mice infected with Pseudomonas aeruginosa. Enrollment in the Ph1b study is ongoing and Calithera expects to share interim data in 2021. In November, Calithera was awarded up to $2.4M from the Cystic Fibrosis Foundation to support clinical development of CB-280.



INCB001158 program continued progress. INCB001158, an internally discovered molecule, is being evaluated in multiple clinical trials for the treatment of patients with solid tumors both as a monotherapy, in combination with anti-PD-1 immunotherapy, and in multiple chemotherapy regimens. While Calithera remains committed to and confident in the INCB001158 development program, Calithera decided to opt out of co-development obligations with Incyte in order to focus resources on internal development programs.



Preclinical data presented from CB-668 IL4I1 program. CB-668 is an investigational first-in-class, potent, orally administered IL4I1 inhibitor as a novel immuno-oncology approach to cancer. New preclinical data for CB-668 will be presented at the Society for Immunotherapy of Cancer (SITC) Virtual Meeting November 11-14, 2020.

Selected Third Quarter 2020 Financial Results

Cash, cash equivalents and investments totaled $137.7 million at September 30, 2020.

Research and development expenses were $18.2 million for the three months ended September 30, 2020, compared to $17.2 million for the same period in the prior year. The increase of $1.0 million was due to a $1.9 million increase in the telaglenastat program and a $1.5 million increase in the CB-280 program, partially offset by a $1.0 million decrease in the INCB001158 program and a decrease of $1.4 million in early stage research.

General and administrative expenses were $4.7 million for the three months ended September 30, 2020, compared with $3.9 million for the same period in the prior year. The increase of $0.8 million was primarily related to an increase in higher personnel-related and facility costs.

Interest and other income, net was $0.2 million for the three months ended September 30, 2020, compared to $0.8 million for the same period in the prior year, mainly as a result of lower interest rates.

Net loss for the three months ended September 30, 2020 was $22.7 million, or $0.32 per share.

Conference Call Information

Calithera will host an update conference call today, Thursday, November 5, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 and referring to conference ID 6869011. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at https://ir.calithera.com/investor-overview. The webcast will be recorded and available for replay on Calithera’s website for 30 days.

About Calithera

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “poised” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Calithera’s clinical trials, the clinical and commercial potential of its product candidates; the receipt of top-line efficacy and safety data in the CANTATA trial; the timing of enrollment of the randomized trial in NSCLC patients with genetic mutation NRF2/KEAP1 and the presentation of interim data from this trial; the safety and anti-tumor activity of telaglenastat and cabozantinib, telaglenastat in combination with everolimus, and telaglenastat plus Ibrance; the development of INCB001158 by Calithera and Incyte; and the timing that CB-280 will enter clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and other risk factors affecting Calithera’s business can be found in Calithera’s periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

SOURCE: Calithera Biosciences, Inc.


     Three Months Ended
September 30,
    Nine Months Ended
September 30,
     2020     2019     2020     2019  

Operating expenses:


Research and development

   $ 18,157     $ 17,221     $ 53,938     $ 58,388  

General and administrative

     4,744       3,906       14,786       12,054  













Total operating expenses

     22,901       21,127       68,724       70,442  













Loss from operations

     (22,901     (21,127     (68,724     (70,442

Interest and other income, net

     167       834       1,153       2,310  













Net loss

   $ (22,734   $ (20,293   $ (67,571   $ (68,132













Net loss per share, basic and diluted

   $ (0.32   $ (0.38   $ (0.99   $ (1.52













Weighted-average common shares used to compute net loss per share, basic and diluted

     70,559       53,775       68,219       44,703  













Calithera Biosciences, Inc.    

Selected Consolidated Balance Sheet Financial Data    

(in thousands)    



     September 30,      December 31,  
     2020      2019  

Balance Sheet Data:


Cash, cash equivalents and investments

   $ 137,749      $ 157,361  

Working capital

     120,235        140,172  

Total assets

     147,708        168,768  

Total liabilities

     25,112        26,342  

Accumulated deficit

     (353,672      (286,101

Total stockholders’ equity

     122,596        142,426  


Investor Relations

Jennifer McNealey





Michele Parisi

Sam Brown, Inc.



EX-101.SCH 3 cala-20201105.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cala-20201105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cala-20201105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g53133g1105132038743.jpg GRAPHIC begin 644 g53133g1105132038743.jpg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end XML 7 d53133d8k_htm.xml IDEA: XBRL DOCUMENT 0001496671 2020-11-05 2020-11-05 false 0001496671 8-K 2020-11-05 Calithera Biosciences, Inc. DE 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco CA 94080 (650) 870-1000 false false false false Common Stock, 0.0001 par value CALA NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 05, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001496671
Document Type 8-K
Document Period End Date Nov. 05, 2020
Entity Registrant Name Calithera Biosciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36644
Entity Tax Identification Number 27-2366329
Entity Address, Address Line One 343 Oyster Point Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 870-1000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, 0.0001 par value
Trading Symbol CALA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d53133d8k.htm cala-20201105.xsd cala-20201105_lab.xml cala-20201105_pre.xml d53133dex991.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d53133d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d53133d8k.htm" ] }, "labelLink": { "local": [ "cala-20201105_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cala-20201105_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cala-20201105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cala", "nsuri": "http://www.calithera.com/20201105", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d53133d8k.htm", "contextRef": "duration_2020-11-05_to_2020-11-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d53133d8k.htm", "contextRef": "duration_2020-11-05_to_2020-11-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.calithera.com//20201105/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-20-286832-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-286832-xbrl.zip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end